1 / 3

Gene Therapy for Arthritis, Musculoskeletal, and Skin Diseases

Gene Therapy for Arthritis, Musculoskeletal, and Skin Diseases. Group leaders and participants -Dr. Glen Nuckolls -Dr. Paul Robbins Program Director • Professor, Microbiology and Molecular Genetics, Division of Musculoskeletal Diseases, NIAMS and Biochemistry University of Pittsburgh

Download Presentation

Gene Therapy for Arthritis, Musculoskeletal, and Skin Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Gene Therapy for Arthritis, Musculoskeletal, and Skin Diseases Group leaders and participants -Dr. Glen Nuckolls-Dr. Paul Robbins Program Director •Professor, Microbiology and Molecular Genetics, Division of Musculoskeletal Diseases, NIAMSand Biochemistry University of Pittsburgh -Dr. Carl C. Baker Program Director Division of Skin and Rheumatic Diseases, NIAMS-Dr. Dennis Roop •Charles C. Gates Chair of Regenerative Medicine and Stem Cell Biology -Ms. Shahnaz KhanUniversity of Colorado Denver Clinical Coordinator Division of Extramural Research Activities, NIAMS -Ms. Anna Nicholson Clinical Coordinator Division of Extramural Research Activities, NIAMS -Dr. Louise Rosenbaum Science Policy Analyst Office of Science Policy and Planning, NIAMS Overarching question -What high priority, basic research questions should be addressed to advance the field of gene therapy? 2008 NIAMS Scientific Retreat

  2. Uses of Gene Therapy • Advantages of gene therapy (GT) -Potential replacement or correction of single gene defects -Up- or down-regulation of pathways involved in pathology or natural repair mechanisms -Synthesis, processing, and delivery of GT products at the disease site • Application of GT to Arthritis, Musculoskeletal, and Skin Diseases -Wound-healing: delivery of platelet-derived growth factor b gene to lesions -Rheumatoid arthritis: injection of ex vivo-manipulated synovial cells into joints -Osteoarthritis: targeting interleukin 1 receptor antagonist gene to affected knee joints -Limb-girdle muscular dystrophy: intramuscular delivery of alpha-sarcoglycan gene 2008 NIAMS Scientific Retreat

  3. Points of consideration • Vector optimization, selection, and delivery -In vivo delivery, ex vivo manipulation options -Stem cells: only curative approach • Immune response -Primary obstacle for successful GT -Approaches: transient immune suppression, long-term tolerance strategies • Infrastructure and resource needs -Central services for pre-clinical testing and vector production -Activities (meetings, funding opportunities) to facilitate formation of multidisciplinary collaborations • Regulatory and review issues -Increased federal requirements -Importance of multidisciplinary peer review for GT grant applications 2008 NIAMS Scientific Retreat

More Related